Evidence map›Paper›PMID 41705137›Full record

ReviewInternational journal of pharmaceutics: X2026

Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease-Unveiling challenges and prospects.

Lili Gu, Jiayi Liu, Can Wang, Xiaoqin Shan, Siyi Li, Xinyue Zhang, Lijie Xia, Jinyao Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lili GuInstitute of Materia Medica & College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Jiayi LiuKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of pharmacy, Hangzhou medical college, Hangzhou, Zhejiang 310013, China.
Can WangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of pharmacy, Hangzhou medical college, Hangzhou, Zhejiang 310013, China.
Xiaoqin ShanKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of pharmacy, Hangzhou medical college, Hangzhou, Zhejiang 310013, China.
Siyi LiKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of pharmacy, Hangzhou medical college, Hangzhou, Zhejiang 310013, China.
Xinyue ZhangKey Laboratory of Neuropsychiatric Drug Research of Zhejiang Province, School of pharmacy, Hangzhou medical college, Hangzhou, Zhejiang 310013, China.
Lijie XiaInstitute of Materia Medica & College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.
Jinyao LiInstitute of Materia Medica & College of Life Science and Technology, Xinjiang University, Urumqi 830017, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by cognitive and behavioral issues, posing significant public health challenges. Small interfering RNAs (siRNAs) offer the potential to selectively silence AD-related pathogenic genes. This review first outlines the diverse pathogenic mechanisms and hallmark pathologies of AD, then spotlights the key genes now being silenced by siRNA for therapeutic intervention. These genes encompass those directly implicated in amyloidogenesis, tau phosphorylation, and neuroinflammation, along with those aberrantly up-regulated and associated with AD pathology. Finally, it summarizes recent research on non-viral and local siRNA delivery strategies including lipid, polymer, quantum dots, inorganic materials, extracellular vesicles, and conjugates aimed at effectively penetrating the blood-brain barrier while overcoming intra- and extracellular barriers to target key AD pathways. These findings underscore the promise of siRNA therapy in addressing AD pathology and provide valuable insights into overcoming delivery challenges.

Indexed as

Alzheimer's diseaseCellular deliveryNanoparticlesSmall interference RNA therapeutics

Identifiers

PMID41705137
PMCPMC12908064

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.